Results 111 to 120 of about 77,746 (246)

OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα

Advanced Science, EarlyView.
This study elucidates a novel mechanistic role of the deubiquitinase OTUD6A in asthma pathogenesis, uncovering its regulatory function in airway inflammation and airway remodeling through the stabilization of hResistin/mRELMα. This study offers a novel regulatory axis (OTUD6A‐hResistin/mRELMα) in asthma pathogenesis and OTUD6A inhibition as a potential
Weiting Pan, Xinru Xi, Wei Dai, Tingfang Xiao, Yeqing Chen, Xuanyu Chen, Xiangting Ge, Chengguang Zhao, Hui Zhang, Yali Zhang, Weixi Zhang   +10 more
wiley   +1 more source

USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer

Advanced Science, EarlyView.
USP35 stabilizes ID3 expression by deubiquitinating the K2/K30 site, thereby upregulating PD‐L1 and promoting immune escape in colorectal cancer. IU1, an inhibitor of USP35 enzyme activity, has been shown to inhibit USP35, thereby accelerating ID3 degradation, enhancing CD8+ T cell killing, and reversing the immunosuppressive microenvironment ...
Wenxin Chen, Ling Wang, Hongmei Fan, Lisheng Li, Lingyu Zhang, Ruoxin Li, Fang Liu, Fuli Wen, Yunbin Ye, Chuanzhong Huang   +9 more
wiley   +1 more source

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics. [PDF]

Clin Exp Allergy, 2021
McCrae C, Olsson M, Gustafson P, Malmgren A, Aurell M, Fagerås M, Da Silva CA, Cavallin A, Paraskos J, Karlsson K, Wingren C, Monk P, Marsden R, Harrison T.   +13 more
europepmc   +1 more source

Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas

Advanced Science, EarlyView.
Multiomics integration analysis reveals the “cystic fluid–tumor cell” metabolic coupling that mediates active choline/ethanolamine uptake of tumor cells from cystic fluid and PC/PE synthesis pathways reprogramming that mediating autophagy pathway activation within ACP. ABSTRACT Adamantinomatous craniopharyngioma (ACP), a benign yet highly recurrent and
Dongting Chen, Yahui Gao, Yulin Wang, Ting Lei, Zheng Qu, Yuhan An, Jiaxu Fu, Xin Li, Fangjun Liu, Yan Li   +9 more
wiley   +1 more source

Recurrent Arthritis and Anti-cyclic Citrullinated Peptide Positivity during Interferon-beta 1a Treatment in Two Patients with Multiple Sclerosis

Case Reports in Clinical Practice, 2016
Interferon (IFN) beta is the most widely prescribed disease-modifying drug for multiple sclerosis (MS). However, some adverse reactions are observed in course of IFN-beta therapy.
Hamed Cheraghmakani, Maryam Mobini, Mohammad Baghbanian   +2 more
doaj  

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. [PDF]

Eur J Neurol, 2022
Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, Kappos L, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, De Stefano N.   +14 more
europepmc   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart^® Injector: Results of the Prospective Cohort Study REBIFLECT. [PDF]

Adv Ther, 2022
Rieckmann P, Ziemssen T, Penner IK, Raji A, Wagner T, Richter J, Zettl UK.   +6 more
europepmc   +1 more source

Non‐Targeting shRNA‐Encoded Plasmid DNA Enhances Protective Immunity Through RIDD‐RIG‐I Signaling Pathway in the Zika Virus Animal Model

Advanced Science, EarlyView.
We present a novel DNA vaccine platform featuring intrinsic, non‐targeting dsRNA that significantly enhances immune responses by activating the regulated IRE1‐dependent decay‐RIG‐I signaling pathway. This research elucidates a previously uncharacterized mechanism for dsRNA‐mediated innate immune activation.
Min‐Syuan Huang, Hung‐Chun Liao, Po Peng, Wan‐Ling Wu, Kit Man Chai, Mei‐Yu Chen, Guann‐Yi Yu, Tsung‐Hsien Chuang, Hsin‐Wei Chen, Chuang‐Rung Chang, Shih‐Jen Liu   +10 more
wiley   +1 more source